China-based Innovent Biologics, Inc. (HKG: 1801) has announced a clinical study and supply agreement with Suzhou ForLong Biotechnology Co., Ltd, a collaboration aimed at exploring the potential of Innovent’s sintilimab combined with ForLong’s FL115 in treating advanced solid tumors.
Sintilimab and FL115: A Promising Combination for Cancer Treatment
Sintilimab, a PD-1 immunoglobulin G4 monoclonal antibody co-developed by Innovent and Eli Lilly and Company, has received eight indication approvals in China, with seven of them covered by the National Reimbursement Drug List (NRDL). FL115 is a next-generation long-acting IL-15/IL-15R α monomeric Fc fusion protein that has demonstrated promising preliminary results in Phase III clinical trials in both China and the US. This collaboration seeks to leverage the strengths of both drugs to enhance treatment outcomes for patients with advanced solid tumors.
Terms of the Agreement and Upcoming Clinical Trials
Under the terms of the agreement, Innovent will provide sintilimab for the clinical trials at no cost, while ForLong will conduct a Phase I/II study in China. The study will assess the safety, tolerability, and preliminary efficacy of the combination therapy in cancer patients. This strategic partnership highlights the commitment of both companies to advancing innovative treatments for cancer and improving patient care.-Fineline Info & Tech
